Implications of the presence of an aberrant right hepatic artery in patients undergoing pancreaticoduodenectomy

Table 1 Patient demography n (%)

Patient characteristics	No arterial anomalyn = 182	Arterial anomalyn = 43	P value
Age	52.1 ± 10.9	52.4 ± 11.2	NS
Males/females	135/53	32/11	NS
ASA
I	45 (24.7)	11 (25.6)	NS
II	115 (63.2)	27 (62.7)	NS
III/IV	22 (12.1)	5 (11.6)	NS

ASA: American Society of Anesthesiologists.

Table 2 Underlying disease in patients with and without arterial anomaly n (%)

Indication	No arterial anomaly n = 182	Arterial anomalyn = 43	P value
Ampullary adenocarcinoma	99 (54.4)	23 (53.5)	NS
Distal cholangiocarcinoma	43 (23.6)	10 (23.2)	NS
Pancreatic adenocarcinoma	25 (13.7)	6 (13.9)	NS
Duodenal carcinoma	15 (8.2)	3 (7.0)	NS
GIST	0	1 (2.3)	-

GIST: Gastrointestinal stromal tumor.

Table 3 Hepatic arterial variations observed during pancreaticoduodenectomy n (%)

Arterial variations	n = 43
Replaced RHA from SMA	31 (72.1)
Accessory RHA from SMA	10 (23.2)
Replaced CHA from SMA	1 (2.3)
Accessory RHA from GDA	1 (2.3)

RHA: Right hepatic artery; SMA: Superior mesenteric artery; GDA: Gateway design automation.

Table 4 Intraoperative management of aberrant artery n (%)

Management	n = 43
Dissection and preservation	34 (79)
Ligation	8 (18.6)
Dissection and primary anastomosis	1 (2.3)

Table 5 Intraoperative and postoperative comparison in patients with or without arterial anomalies n (%)

Variables	No arterial anomalyn = 182	Arterial anomalyn = 43	P value
Duration of surgery (min)	420 ± 44 (240-540)	480 ± 45 (300-600)	< 0.05
Blood loss (mL)	360 ± 52 (200-630)	390 ± 45 (300-650)	NS
Postpancreatectomy hemorrhage	4 (2.1)	1 (2.3)	NS
Postpancreatectomy fistula	9 (4.9)	2 (4.65)	NS
Delayed gastric emptying	98 (53.8)	23 (53.4)	NS
Length of hospital stay	13.6 ± 6.0	13.1 ± 5.1	NS
Mortality	3 (1.7)	1 (2.3)	NS
Positive margin	13 (7.1)	3 (6.9)	NS
Lymph node yield	12 ± 4	12 ± 5	NS